Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial.
- DOI
- 10.1158/1078-0432.ccr-26-0819
- Published
- 2026 Aug 19
- Container
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/1078-0432.ccr-26-0819,
title = {Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial.},
author = {Saba NF and Posner M and Harrington K and Neupane P and Rezaee R and Nenclares P and Jimeno A and Denker AE and MacIntyre S and Makris L and Wong D},
year = {2026},
journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
doi = {10.1158/1078-0432.ccr-26-0819},
url = {https://doi.org/10.1158/1078-0432.ccr-26-0819}
}RIS
TY - JOUR TI - Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial. AU - Saba NF AU - Posner M AU - Harrington K AU - Neupane P AU - Rezaee R AU - Nenclares P AU - Jimeno A AU - Denker AE AU - MacIntyre S AU - Makris L AU - Wong D PY - 2026 JO - Clinical cancer research : an official journal of the American Association for Cancer Research DO - 10.1158/1078-0432.ccr-26-0819 UR - https://doi.org/10.1158/1078-0432.ccr-26-0819 ER -
APA
NF, S., M, P., K, H., P, N., R, R., P, N., A, J., AE, D., S, M., L, M., & D, W. (2026). Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-0819
Source records
- pubmed · retrieved 2026-09-26T11:30:02.199Z